NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Inclusion Criteria: * Age ≥ 18 years * Histologically/cytologically confirmed biliary tract cancer * Advanced or metastatic disease that is refractory to gemcitabine or fluoropyrimidine based therapy, or if there is intolerance to these regimens * Measurable disease by RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Anticipated life expectancy of \> 12 weeks * Hemoglobin ≥ 9.0 g/dL (obtained ≤ 14 days prior to registration) * Absolute neutrophil count (ANC) ≥ 1500/mm\^3 (obtained ≤ 14 days prior to registration) * Platelet count ≥ 100,000/mm\^3 (obtained ≤ 14 days prior to registration) * Aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration) * Alanine aminotransferase (ALT) ≤ 5 x ULN (obtained ≤ 14 days prior to registration) * Total bilirubin ≤ 1.5 x ULN (obtained ≤ 14 days prior to registration) * Serum creatinine ≤ 1.5 x ULN (obtained ≤ 14 days prior to registration) * Provide written informed consent * Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only * NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Willing to use a highly effective method of contraception from the first dose of study medication through 180 days after the last dose of study medication, for persons of childbearing potential or persons able to father a child only * Willing to return to enro…